Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 4
Highlights - Full year 2017
Sales development
Sales increased by 2% in local currencies and were unchanged in Danish kroner
International Operations grew by 5% in local currencies
·
•
North America Operations sales were unchanged in local currencies
TresibaⓇ and VictozaⓇ accounted for the largest share of growth and grew by 85% and 18% in local currencies, respectively
Research and Development
OzempicⓇ approved in the US and positive CHMP opinion issued in the EU
Cardiovascular outcomes study, SOUL, for OzempicⓇ to be initiated mid 2018
Phase 3a programme STEP and cardiovascular outcomes study SELECT with semaglutide in obesity to be initiated in 2018
Financials
Operating profit increased by 5% in local currencies and by 1% in Danish kroner
Diluted earnings per share increased by 3% to 15.39 DKK per share
3% increase in total dividend to DKK 7.85 per share of DKK 0.20 proposed (including interim dividend of DKK 3.00 paid in
August 2017)
New share repurchase programme of up to DKK 14 billion to be executed during the coming 12 months
2018 financial outlook:
•
Sales growth is expected to be 2-5% measured in local currencies (around 7% lower reported)
Operating profit growth is expected to be 1-5% measured in local currencies (around 10% lower reported)
changing
diabetes®
novo nordiskView entire presentation